The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.
Open accessAbstract
Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (+/-SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35+/-5.5% and 11+/-1.4%, respectively, compared with a relatively small change of 1.7+/-1.8% and 0+/-0.9% in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5% for the lumbar spine by QCT (P < 0.001) and 9.8% for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150%, whereas markers of bone resorption increased only 100%, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid- induced osteoporosis who are taking hormone replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationBone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Self-citationAlendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationEffect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosis
Riggs, B. L., Hodgson, S. F., O'Fallon, W. M., Chao, E. Y. S., Wahner, H. W., Muhs, J. M., Cedel, S. L., & Melon, L. J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221203 · Cited by 1,088
Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 685
TAM, C. S., HEERSCHE, J. N. M., MURRAY, T. M., & PARSONS, J. A. (1982) · Endocrinology · doi:10.1210/endo-110-2-506 · Cited by 612
Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin
Sambrook, P., Birmingham, J., Kelly, P., Kempler, S., Nguyen, T., Pocock, N., & Eisman, J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282404 · Cited by 520
Dr. Slovik, D. M., Rosenthal, D. I., Doppelt, S. H., Potts, J. T., Daly, M. A., Campbell, J. A., & Neer, R. M. (1986) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650010411 · Cited by 348
Cited by
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris, E. S., Chen, Y.-T., Abbott, T. A., Barrett-Connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1108 · Cited by 1,093
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
ENGINEERING PRINCIPLES OF CLINICAL CELL-BASED TISSUE ENGINEERING
MUSCHLER, G. F., NAKAMOTO, C., & GRIFFITH, L. G. (2004) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200407000-00029 · Cited by 878
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718
Grossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
Dempster, D. W., Cosman, F., Kurland, E. S., Zhou, H., Nieves, J., Woelfert, L., Shane, E., Plavetić, K., Müller, R., Bilezikian, J., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1846 · Cited by 653
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors
Kim, H., Wrann, C. D., Jedrychowski, M., Vidoni, S., Kitase, Y., Nagano, K., Zhou, C., Chou, J., Parkman, V.-J. A., Novick, S. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.025 · Cited by 638
“Yet it has been well established that intermittent PTH treatment is anabolic to the skeleton, at least over the first twelve months of therapy (Dempster et al., 2001; Lane et al., 1998).”
Engelke, K., Adams, J. E., Armbrecht, G., Augat, P., Bogado, C. E., Bouxsein, M. L., Felsenberg, D., Ito, M., Prevrhal, S., Hans, D. B., et al. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.010 · Cited by 617
Jiang, Y., Zhao, J. J., Mitlak, B. H., Wang, O., Genant, H. K., & Eriksen, E. F. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.1932 · Cited by 616
Self-citationOne Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
“This hypothesis is supported by a study which showed that areal lumbar spine BMD, vertebral cross-sectional area, and estimated vertebral compressive strength increased significantly more in postmenopausal women with glucocorticoid-induced OP treated with synthetic hPTH(1–34) plus estrogen compared with those treated…”
ResultPathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Chotiyarnwong, P., & McCloskey, E. V. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0341-0 · Cited by 489
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
Ettinger, B., Martin, S. J., Crans, G., & Pavo, I. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040117 · Cited by 487
Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J. J., Komaba, H., Ando, R., Kakuta, T., Fujii, H., et al. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12058 · Cited by 402
New Developments in the Pathogenesis and Treatment of Steroid-Induced Osteoporosis
Manolagas, S. C., & Weinstein, R. S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.7.1061 · Cited by 388
Riggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Parathyroid hormone: past and present
Potts, J. T. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06057 · Cited by 327
Winer, K. K., Ko, C. W., Reynolds, J. C., Dowdy, K., Keil, M., Peterson, D., Gerber, L. H., McGarvey, C., & Cutler, G. B. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021736 · Cited by 312
Cosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., & Lindsay, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.925 · Cited by 311
Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate1
Rittmaster, R. S., Bolognese, M., Ettinger, M. P., Hanley, D. A., Hodsman, A. B., Kendler, D. L., & Rosen, C. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6614 · Cited by 307
Gut, inflammation and osteoporosis: Basic and clinical concepts
Tilg, H., Moschen, A. R., Kaser, A., Pines, A., & Dotan, I. (2008) · Gut · doi:10.1136/gut.2006.117382 · Cited by 292
Gowen, M., Stroup, G. B., Dodds, R. A., James, I. E., Votta, B. J., Smith, B. R., Bhatnagar, P. K., Lago, A. M., Callahan, J. F., DelMar, E. G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9038 · Cited by 279
Bone quality: where do we go from here?
Bouxsein, M. L. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1489-x · Cited by 264
The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis
van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 260
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
Mechanisms of glucocorticoid-induced osteoporosis.
Canalis, E. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00013 · Cited by 164
Glucocorticoid dose determines osteocyte cell fate
Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157
Pathogenic mechanisms of glucocorticoid-induced osteoporosis
Chen, M., Fu, W., Xu, H., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.002 · Cited by 146
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Self-citationUnderstanding and managing corticosteroid-induced osteoporosis
Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s282606 · Cited by 84
Buxton, E. C., Yao, W., & Lane, N. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032066 · Cited by 79
Self-citationUncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis
Hansen, K. E., Wilson, H. A., Zapalowski, C., Fink, H. A., Minisola, S., & Adler, R. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.362 · Cited by 65
Glucocorticoid-induced osteoporosis
Silverman, S. L., & Lane, N. E. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0005-4 · Cited by 50
Self-citationPrevention of glucocorticoid induced bone changes with beta-ecdysone
Dai, W., Jiang, L., Lay, Y.-A. E., Chen, H., Jin, G., Zhang, H., Kot, A., Ritchie, R. O., Lane, N. E., & Yao, W. (2015) · Bone · doi:10.1016/j.bone.2015.01.001 · Cited by 30
Self-citation
Metadata
- Authors
- Lane, N. E., Sanchez, S., Modin, G. W., Genant, H. K., Pierini, E., & Arnaud, C. D.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-10-15
- Volume
- 102
- Issue
- 8
- Pages
- 1627-1633
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2127733654
- Cited by
- 529
- References
- 26
- FWCI
- 26.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.